Disease · MONDO_0004971
Comparisons in its trials12
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 12 of 12
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Cohort 1 - AL101 4mg vs Cohort 2 - AL101 6mg: deaths from any cause | 41 of 45 | 26 of 42 | 87 | NCT03691207 | Trial comparisons |
| Cohort 1 - AL101 4mg vs Cohort 2 - AL101 6mg: serious adverse events | 23 of 45 | 26 of 42 | 87 | NCT03691207 | Trial comparisons |
| Cohort 1 - AL101 4mg vs Cohort 2 - AL101 6mg: Overall Response Rate (ORR) | 3 of 41 | 2 of 36 | 77 | NCT03691207 | Trial comparisons |
| Cohort 1 - AL101 4mg vs Cohort 2 - AL101 6mg: Clinical Benefit Response Rate (CBR) | 28 of 41 | 24 of 36 | 77 | NCT03691207 | Trial comparisons |
| R/M Adenoid Cystic Carcinoma (ACC) vs R/M SGC of Any Histology, Except ACC (Non ACC): deaths from any cause | 6 of 32 | 7 of 32 | 64 | NCT03172624 | Trial comparisons |
| R/M Adenoid Cystic Carcinoma (ACC) vs R/M SGC of Any Histology, Except ACC (Non ACC): serious adverse events | 18 of 32 | 9 of 32 | 64 | NCT03172624 | Trial comparisons |
| Adenoid Cystic Carcinoma vs Non Adenoid Cystic Carcinoma: serious adverse events | 12 of 40 | 8 of 14 | 54 | NCT00859937 | Trial comparisons |
| Pembrolizumab + Radiation vs Pembrolizumab: Number of Participants With Complete Response (Absence of Non-irradiated Lesions on Scans) | 0 of 10 | 0 of 10 | 20 | NCT03087019 | Trial comparisons |
| Pembrolizumab + Radiation vs Pembrolizumab: Number of Participants With Partial Response (Tumor Size on Scans) | 0 of 10 | 0 of 10 | 20 | NCT03087019 | Trial comparisons |
| Pembrolizumab + Radiation vs Pembrolizumab: deaths from any cause | 1 of 10 | 1 of 10 | 20 | NCT03087019 | Trial comparisons |
| Pembrolizumab + Radiation vs Pembrolizumab: serious adverse events | 3 of 10 | 4 of 10 | 20 | NCT03087019 | Trial comparisons |
| Pembrolizumab + Radiation vs Pembrolizumab: Patients Demonstrating Objective Response In Non-Irradiated Lesions (Tumor Size on Scans) | 0 of 10 | 0 of 9 | 19 | NCT03087019 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0004971/comparisons